Exploration of Neuroscience

Table 2. Ongoing clinical trials of T cell engager therapies in glioblastoma.

NCT number	Intervention	T-cell engager antigen target	Indications	Trial phase	Primary endpoint	Delivery route
NCT04903795	Bispecific T cell engager therapy post radiation plus temozolomide	EGFRvIII	Grade 4 glioma with EGFRvIII mutation	Phase 1	Dose-limiting toxicity	Bolus injection
NCT06814496	Combination bispecific T cell engager therapy (Tarlatamab) with radiation	DLL3	Glioblastoma, melanoma, Merkel cell carcinoma, medullary thyroid cancer, sinonasal undifferentiated cancer, esthesioneuroblastoma, bladder cancer, testicular cancer, cervical cancer, large cell neuroendocrine lung cancer, and non-small cell lung cancer	Phases 1 and 2	Dose-limiting toxicity	Infusion

Return to article view

EGFRvIII: epidermal growth factor receptor variant III; DLL3: delta-like ligand 3.

Declarations

Author contributions

AHL: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. MA: Conceptualization. Both authors read and approved the submitted version.

Conflicts of interest

Both authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

All datasets analyzed for this study are included in the main text and the references.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Baugh R, Khalique H, Page E, Lei-Rossmann J, Wan PK, Johanssen T, et al. Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells. J Immunother Cancer. 2024;12:e008460. [DOI] [PubMed] [PMC]

Stupp R, Mason WP, Bent MJvd, Weller M, Fisher B, Taphoorn MJB, et al.; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96. [DOI] [PubMed]

Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6:1003–10. [DOI] [PubMed] [PMC]

Ameratunga M, Coleman N, Welsh L, Saran F, Lopez J. CNS cancer immunity cycle and strategies to target this for glioblastoma. Oncotarget. 2018;9:22802–16. [DOI] [PubMed] [PMC]

Tiwari S, Han Z. Immunotherapy: Advancing glioblastoma treatment-A narrative review of scientific studies. Cancer Rep (Hoboken). 2023;7:e1947. [DOI] [PubMed] [PMC]

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018;16:142. [DOI] [PubMed] [PMC]

Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, et al. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. N Engl J Med. 2024;390:1290–8. [DOI] [PubMed] [PMC]

Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro Oncol. 2023;25:339–50. [DOI] [PubMed] [PMC]

Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69. [DOI] [PubMed] [PMC]

10.

Rolin C, Zimmer J, Seguin-Devaux C. Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases. Cell Mol Immunol. 2024;21:643–61. [DOI] [PubMed] [PMC]

11.

Yin Y, Rodriguez JL, Li N, Thokala R, Nasrallah MP, Hu L, et al. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. Mol Ther. 2022;30:2537–53. [DOI] [PubMed] [PMC]

12.

Ahn M, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, et al.; DeLLphi-301 Investigators. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N Engl J Med. 2023;389:2063–75. [DOI] [PubMed]

13.

Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain J, Schlaak M, Butler MO, et al. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2023;389:2256–66. [DOI] [PubMed] [PMC]

14.

Dowlati A, Hummel H, Champiat S, Olmedo ME, Boyer M, He K, et al. Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update. J Clin Oncol. 2024;42:3392–9. [DOI] [PubMed] [PMC]

15.

Bhojnagarwala PS, O’Connell RP, Park D, Liaw K, Ali AR, Bordoloi D, et al. In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme. Mol Ther Oncolytics. 2022;26:289–301. [DOI] [PubMed] [PMC]

16.

Brosius SN, Manley W, Harvey K, Gallanaugh J, Rohacek D, Anderson S, et al. Interneurons that BiTE: Harnessing the migratory capacity of cortical inhibitory interneuron precursors to treat high-grade glioma. bioRxiv [Preprint]. 2024 [cited 2025 Sep 15]. Available from: https://www.biorxiv.org/content/10.1101/2024.04.29.591530v1

17.

Singh K, Hotchkiss KM, Mohan AA, Reedy JL, Sampson JH, Khasraw M. For whom the T cells troll? Bispecific T-cell engagers in glioblastoma. J Immunother Cancer. 2021;9:e003679. [DOI] [PubMed] [PMC]

18.

Pituch KC, Zannikou M, Ilut L, Xiao T, Chastkofsky M, Sukhanova M, et al. Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity. Proc Natl Acad Sci U S A. 2021;118:e2015800118. [DOI] [PubMed] [PMC]

19.

Gardell JL, Matsumoto LR, Chinn H, DeGolier KR, Kreuser SA, Prieskorn B, et al. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma. J Immunother Cancer. 2020;8:e001202. [DOI] [PubMed] [PMC]

20.

Subklewe M. BiTEs better than CAR T cells. Blood Adv. 2021;5:607–12. [DOI] [PubMed] [PMC]

21.

Park DH, Bhojnagarwala PS, Liaw K, Bordoloi D, Tursi NJ, Zhao S, et al. Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells. J Immunother Cancer. 2024;12:e009604. [DOI] [PubMed] [PMC]

22.

Park DH, Liaw K, Bhojnagarwala P, Zhu X, Choi J, Ali AR, et al. Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape. Mol Ther Oncolytics. 2023;28:249–63. [DOI] [PubMed] [PMC]

23.

Sharma P, Aaroe A, Liang J, Puduvalli VK. Tumor microenvironment in glioblastoma: Current and emerging concepts. Neurooncol Adv. 2023;5:vdad009. [DOI] [PubMed] [PMC]

24.

Zannikou MZ, Duffy JT, Procissi D, Najem H, Levine RN, Hambardzumyan D, et al. A Bi-Specific T Cell-Engaging Antibody Shows Potent Activity, Specificity, and Tumor Microenvironment Remodeling in Experimental Syngeneic and Genetically Engineered Models of GBM. bioRxiv [Preprint]. 2025 [cited 2025 Sep 15]. Available from: https://www.biorxiv.org/content/10.1101/2024.12.18.628714v2 [PubMed] [PMC]

25.

Choi MJ, So EY, Akosman B, Lee YE, Raufi AG, Bertone P, et al. Enabling CAR-T Cell Immunotherapy in Glioblastoma by Modifying Tumor Microenvironment via Oncolytic Adenovirus Encoding Bispecific T Cell Engager. bioRxiv [Preprint]. 2025 [cited 2025 Sep 15]. Available from: https://www.biorxiv.org/content/10.1101/2025.07.30.667708v1

26.

Rosenthal MA, Balana C, van Linde ME, Sayehli C, Fiedler WM, Wermke M, et al. ATIM-49 (LTBK-01). AMG 596, a novel anti-EGFRvIII bispecific T cell engager (BITE®) molecule for the treatment of glioblastoma (GBM): planned interim analysis in recurrent GBM (RGBM). Neuro-Oncol. 2019;21:vi283–5. [DOI] [PMC]

27.

Sternjak A, Lee F, Thomas O, Balazs M, Wahl J, Lorenczewski G, et al. Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII. Mol Cancer Ther. 2021;20:925–33. [DOI] [PubMed]

28.

Huynh V, Tatari N, Marple A, Savage N, McKenna D, Venugopal C, et al. Real-time evaluation of a hydrogel delivery vehicle for cancer immunotherapeutics within embedded spheroid cultures. J Control Release. 2022;348:386–96. [DOI] [PubMed]

29.

Li G, Zhang Z, Cai L, Tang X, Huang J, Yu L, et al. Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma. Oncoimmunology. 2021;10:1983306. [DOI] [PubMed] [PMC]

30.

Arnone CM, Polito VA, Mastronuzzi A, Carai A, Diomedi FC, Antonucci L, et al. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021;9:e001930. [DOI] [PubMed] [PMC]

31.

Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019;37:1049–58. [DOI] [PubMed]

32.

García-Montaño LA, Licón-Muñoz Y, Martinez FJ, Keddari YR, Ziemke MK, Chohan MO, et al. Dissecting Intra-tumor Heterogeneity in the Glioblastoma Microenvironment Using Fluorescence-Guided Multiple Sampling. Mol Cancer Res. 2023;21:755–67. [DOI] [PubMed] [PMC]

33.

Coy S, Lee JS, Chan SJ, Woo T, Jones J, Alexandrescu S, et al. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors. Neuro Oncol. 2024;26:458–72. [DOI] [PubMed] [PMC]

34.

Barish ME, Weng L, Awabdeh D, Zhai Y, Starr R, D’Apuzzo M, et al. Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma. Neoplasia. 2022;30:100801. [DOI] [PubMed] [PMC]

35.

Philippova J, Shevchenko J, Sennikov S. GD2-targeting therapy: a comparative analysis of approaches and promising directions. Front Immunol. 2024;15:1371345. [DOI] [PubMed] [PMC]

36.

Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016;375:2561–9. [DOI] [PubMed] [PMC]

37.

O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9:eaaa0984. [DOI] [PubMed] [PMC]

38.

Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, et al. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020;126:3192–201. [DOI] [PubMed]

39.

Iwahori K, Kakarla S, Velasquez MP, Yu F, Yi Z, Gerken C, et al. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther. 2015;23:171–8. [DOI] [PubMed] [PMC]

40.

Hart E, Odé Z, Derieppe MPP, Groenink L, Heymans MW, Otten R, et al. Blood-brain barrier permeability following conventional photon radiotherapy - A systematic review and meta-analysis of clinical and preclinical studies. Clin Transl Radiat Oncol. 2022;35:44–55. [DOI] [PubMed] [PMC]

41.

Woroniecka KI, Rhodin KE, Chongsathidkiet P, Keith KA, Fecci PE. T-cell Dysfunction in Glioblastoma: Applying a New Framework. Clin Cancer Res. 2018;24:3792–802. [DOI] [PubMed] [PMC]

42.

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018;379:722–30. [DOI] [PubMed] [PMC]

43.

Reardon DA, Kim TM, Frenel J, Simonelli M, Lopez J, Subramaniam DS, et al. Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial. Cancer. 2021;127:1620–9. [DOI] [PubMed]

44.

Reardon DA, Kaley TJ, Dietrich J, Clarke JL, Dunn G, Lim M, et al. Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM). J Clin Oncol. 2019;37:2032. [DOI]

45.

Arvedson T, Bailis JM, Urbig T, Stevens JL. Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies. Curr Opin Biotechnol. 2022;78:102799. [DOI] [PubMed]